NEW YORK – Robert Noecker, MD, gives his pearls on adopting minimally invasive glaucoma surgery.
Uncategorized
Uncategorized
Phase 3 trial evidence supports use of aflibercept in DME
BOSTON — Among “lessons learned” from the VIVID and VISTA trials is that aflibercept is an effective treatment for patients with center-involved diabetic macular edema, according to one presenter at Macula 2015.“The totality of the evidence suggests that aflibercept is a very effective and safe treatment for our patients with DME,” Diana V. Do, MD, said at Macula 2015, adding that the diabetic retinopathy severity score improves with use of the drug as well.
Patient Satisfaction Equal for Competing Multifocal Lenses
Two commonly used multifocal lenses provided similar outcomes for patients in a randomized controlled trial, with four of five patients spectacle-free after implantation in each group. Medscape Medical News
BioLight invests in newly-formed ophthalmic company
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world…
Uncategorized
Argus II Retinal Prosthesis System approved in Canada
The Argus II Retinal Prosthesis System has been approved by Health Canada to treat patients with severe to profound outer retinal degeneration, according to a press release from Second Sight Medical Products.The Argus II induces visual perception in bl…
Uncategorized
Early termination of HSR Act waiting period granted for Actavis’ acquisition of Allergan
Actavis and Allergan have announced that the U.S. Federal Trade Commission has allowed early termination of the Hart-Scott-Rodino Antitrust Improvement Act of 1976 waiting period with respect to Actavis’ pending acquisition of Allergan.The companies have set the close of business on Jan. 22 as the record date for determining shareholders that will be allowed to vote at their respective special meetings of shareholders, which will be held in connection with the pending acquisition, according to a press release.